Sutro Biopharma, Inc. (STRO) - Form 8-K Summary
Business Context and Reporting Period
Sutro Biopharma, Inc., a Delaware corporation, filed this Current Report on Form 8-K on May 14, 2026. The filing announces the financial results for the quarter ended March 31, 2026. The company's common stock trades on The Nasdaq Global Market under the symbol STRO.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) containing the actual financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for any financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text, as the specific financial results are contained in the referenced press release exhibit.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished under Item 2.02, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, management commentary, risks, or unusual items are described in the text of this 8-K form itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Confirm if the company has issued any forward-looking guidance for the remainder of 2026 in the press release.